Detection of carbapenemase producing Acinetobacter baumannii ST19 from Georgia and Ukraine carrying blaOXA-23, blaOXA-72, and/or blaNDM-5, December 2019 to June 2023-Reference-Cited by-同舟云学术

Detection of carbapenemase producing Acinetobacter baumannii ST19 from Georgia and Ukraine carrying blaOXA-23, blaOXA-72, and/or blaNDM-5, December 2019 to June 2023

Published:2024-06-13 Issue:24 Volume:29 Page:
ISSN:1560-7917
Container-title:Eurosurveillance
language:en
Short-container-title:

Author:

Luo Ting L¹,Martin Melissa J¹,Kovalchuk Valentyn²,Kondratiuk Viacheslav³,Trapaidze Nino⁴,Metreveli Magda⁴,Hulseberg Christine E⁴,Dao Henry D⁵¹,Kwak Yoon I¹,Maybank Rosslyn¹,Musich Thomas A⁴,Scherer Matthew R⁴,Bennett Jason W¹,Mc Gann Patrick T¹,Lebreton Francois¹^ORCID

Affiliation:

1. Multidrug-Resistant Organism Repository and Surveillance Network (MRSN), Walter Reed Army Institute of Research, Silver Spring, Maryland, United States

2. Department of Microbiology, National Pirogov Memorial Medical University, Vinnytsia, Ukraine

3. Department of Emergency and Military Medicine, National Pirogov Memorial Medical University, Vinnytsia, Ukraine

4. US Army Medical Research Directorate - Europe & Middle East, Tbilisi, Georgia

5. Landstuhl Regional Medical Center, Landstuhl, Germany

Abstract

In 2003−2023, amid 5,436 Acinetobacter baumannii isolates collected globally through the Multidrug-Resistant Organism Repository and Surveillance Network, 97 were ST19PAS, 34 of which carbapenem-resistant. Strains (n = 32) sampled after 2019 harboured either bla OXA-23, bla OXA-72, and/or bla NDM-5. Phylogenetic analysis of the 97 isolates and 11 publicly available ST19 genomes revealed three sub-lineages of carbapenemase-producing isolates from mainly Ukraine and Georgia, including an epidemic clone carrying all three carbapenemase genes. Infection control and global surveillance of carbapenem-resistant A. baumannii remain important.

Publisher

European Centre for Disease Control and Prevention (ECDC)

Reference23 articles.

1. Surveillance, characterisation, and preservation of multidrug-resistant bacteria.;Lesho;Lancet Infect Dis,2011

2. A multidrug-resistance surveillance network: 1 year on.;Waterman;Lancet Infect Dis,2012

3. Multidrug-resistant, extensively drug-resistant and pandrug-resistant bacteria: an international expert proposal for interim standard definitions for acquired resistance.;Magiorakos;Clin Microbiol Infect,2012

4. A diverse panel of clinical Acinetobacter baumannii for research and development.;Galac;Antimicrob Agents Chemother,2020

5. Clinical and Laboratory Standards Institute (CLSI). Performance Standards for Antimicrobial Susceptibility Testing. 33rd ed. CLSI Supplement M100. CLSI; 2023. Available from: https://clsi.org/media/tc4b1paf/m10033_samplepages-1.pdf